1. HBW Insight
  2. >>Beauty
  3. >>Policy & Regulation
  4. >>Regulation

Senate Health Committee To Move On Cosmetics; News In Brief

Cosmetics reform legislation is slated for markup April 18, according to Senate Health Committee leadership. In other news, ECHA continues working to support 2018 REACH registrants, and IFRA North America names a new chief regulatory scientist and communications director.

The Senate Health, Education, Labor and Pensions Committee aims to put out a staff discussion draft on cosmetics reform by Feb. 23 and mark up related legislation April 18, according to a Feb. 8 statement on the committee's spring agenda released by Chairman Lamar Alexander, R-Tenn., and Ranking Member Patty Murray, D-Wash. The lawmakers do not cite a specific cosmetics bill, with two proposals currently under Senate consideration. (Also see "Surprise Hatch Bill Lays Middle Ground For Cosmetic Regulatory Reform" - HBW Insight, 26 October, 2017.)

Their planned markup session in April also will include the draft Over-the-Counter Drug Safety Innovation and Reform Act, the committee...

More from Regulation

More from Policy & Regulation

House Bill Aims to ‘Modernize’ US FDA’s Review Process For Sunscreens

 
• By Eileen Francis

Four co-chairs of the House of Representatives’ Skin Cancer Caucus have introduced the Safe Sunscreen Standards Act to direct FDA to establish clearer, ‘more flexible’ standards for evaluating sunscreen ingredients.

Beauty Industry: Counter Impact Of State Legislation By Connecting With Lawmakers – IBA

 
• By Eileen Francis

Beauty stakeholders will undoubtedly feel the impact of new state laws targeting cosmetic ingredients and packaging and should therefore open lines of communication with state lawmakers.

FDA’s FY 2026 Budget Request Lacks New Policy Proposals

 
• By Sue Sutter

The White House requested $6.8bn for the FDA, down 3.9% from the current funding level, but does not propose any legislative changes. In previous years, the agency used the budget process to seek statutory fixes specific to generic drugs and shortages.